Brock Merritt, DO
Family Medicine · Phoenix, AZNPI 1619933942
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations.
Across 85 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$232
- Redhill Biopharma Inc.$186
- AstraZeneca$154
- Pfizer$143
- Abbott$104
- Cranial Technologies, Inc$82
- plus $595 from 16 others
Across 296 payments — averaging $28,308 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bavarian Nordic A/s$5M
- Pfizer$2M
- Modernatx, Inc.$522K
- AbbVie$512K
- Eli Lilly$303K
- Eisai Inc.$17K
- plus $42K from 5 others
What the payments were for
- Food & beverage$1,496100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 11 | $232 |
| Redhill Biopharma Inc. | 8 | $186 |
| AstraZeneca | 11 | $154 |
| Pfizer | 14 | $143 |
| Abbott | 5 | $104 |
| Cranial Technologies, Inc | 5 | $82 |
| AbbVie | 4 | $67 |
| Boston Scientific | 3 | $56 |
| Dexcom, Inc. | 2 | $55 |
| GSK | 3 | $44 |
| Exact Sciences | 2 | $43 |
| Lucid Diagnostics Inc. | 1 | $42 |
| Amarin Pharma, Inc. | 3 | $40 |
| Novo Nordisk | 2 | $39 |
| Amgen | 2 | $36 |
| Johnson & Johnson | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Sarepta Therapeutics, Inc. | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $23 |
| Vivus LLC | 1 | $22 |
| Abiomed | 1 | $18 |
How this compares
$1,496 in reported general payments places this provider in the 75th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 23 | $26,169 |
| OzempicSemaglutide | 11 | $17,454 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,514 |
| Atorvastatin Calcium | 52 | $561 |
| Gabapentin | 25 | $541 |
| Metformin Hcl | 62 | $502 |
| Levothyroxine Sodium | 37 | $397 |
| Losartan Potassium | 30 | $368 |
| Metoprolol Succinate | 28 | $333 |
| Ibuprofen | 13 | $321 |
| Pantoprazole Sodium | 22 | $303 |
| Amlodipine Besylate | 30 | $250 |
| Lisinopril | 40 | $202 |
| Trazodone Hcl | 13 | $184 |
| Tamsulosin Hcl | 14 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $143 | $26,16923 claims |
| Novo NordiskOzempic | $39 | $17,45411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Phoenix
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Heather ElwoodPhoenix$236K
- Ahmed AghaPhoenix$92K
- Valerie MirandaPhoenix$91K
- Randy GelowPhoenix$56K
- Gabrielle GoodrickPhoenix$32K
- Trisha TavaresPhoenix$32K
- Donald MulvaneyPhoenix$21K
- Carlos GarretonPhoenix$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.